<H1>Chapter DOI: 10.1208/aapsj070476<br/>Cited-By Count: 20</H1><table border="1" width="30%"><tr><td>Total References</td><td>38</td></tr><tr><td>Springer references</td><td>15</td></tr><tr><td>Non Springer references</td><td>23</td></tr><tr><td>BibStructured Count</td><td width="10%">35</td></tr><tr><td>BibUnstructured Count</td><td width="10%">3</td></tr><tr><td>DOI already available in SpringerLink</td><td>21</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>5</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>2</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>6</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>7</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The &#8220;wooden shoe&#8221; paradigm.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1997;32:259&#8211;267.</td><td><a href=http://dx.doi.org/10.2165/00003088-199732040-00001>10.2165/00003088-199732040-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibChapter</td><td>Levy G. The case for preclinical pharmacodynamics. In: Yacobi A, Skelly JP, Shah VP, Benet LZ, eds.<Emphasis Type="Italic">Integration of Pharmacokinetics. Pharmacodynamics and Toxicokinetics in Rational Drug Development</Emphasis>. New York, NY: Plenum Press, 1993:7&#8211;13.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-4757-1520-0>10.1007/978-1-4757-1520-0</a></td><td><b>CrossRef-Meta</b></td>
<td>Year</td><td>CrossRef</td></tr><tr><td>CR3</td><td>BibChapter</td><td>Gabrielsson JH, Luthman J, van der Graaf PH. Utility of kineticdynamic reasoning in decision making in drug candidate selection. In: Danhof M, Karlsson M, Powel RJ, eds.<Emphasis Type="Italic">Measurement and Kinetics of In Vivo Drug Effects</Emphasis>.<Emphasis Type="Italic">Advances in Simultaneous Pharmacokinetic/ Pharmacodynamic Modelling</Emphasis>.<Emphasis Type="Italic">Vol 1</Emphasis>. The Netherlands: Nordwijkerhout; 2002:161&#8211;165.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>US Food and Drug Administration. FDA Modernization Act of 1997</span>. <span style='background:#FFD9B3'>Food and Drug Administration Web site</span>. <span style='background:#FFFF0F'>Available at: www.fda.gov. Accessed October 2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>US</span> <span style='background:#BCBCBC'>Food</span></span> and <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>Drug</span> <span style='background:#BCBCBC'>Administration</span></span></aug>. <span style='background:#FFD9B3'>Providing clinical evidence of effectiveness for human drugs and biological products</span>. Food and Drug Administration Web site. <span style='background:#FFFF0F'>Available at: www.fda.gov. Accessed October 2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>D&#8217;Argenio DZ. Optimal sampling times for pharmacokinetic experiments.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1981;9:739&#8211;756.</td><td><a href=http://dx.doi.org/10.1007/BF01070904>10.1007/BF01070904</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>US</span> <span style='background:#BCBCBC'>Congress</span></span></aug>. <span style='background:#FFD9B3'><i>Pharmaceutical R & D: Costs, Risks and Rewards</i></span>. <span style='background:#C0FFC0'>Washington, DC</span>: <span style='background:#FFFF49'>US Government Printing Office</span>, <span style='background:#66FF66'>1993</span>:<span style='background:#FFFF0F'>OTA-H-522</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibBook</td><td>Kaitin KI.<Emphasis Type="Italic">Outlook 2002</Emphasis>. Boston, MA: Tufts Center for the Study of Drug Development, Tufts University; 2002.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1990;18:347&#8211;360.</td><td><a href=http://dx.doi.org/10.1007/BF01062273>10.1007/BF01062273</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Retout S, Mentre F, Bruno R. Fisher information matrix for nonlinear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.<Emphasis Type="Italic">Stat Med</Emphasis>. 2002;21:2623&#8211;2639.</td><td><a href=http://dx.doi.org/10.1002/sim.1041>10.1002/sim.1041</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibBook</td><td>Atkinson AC, Donev AN.<Emphasis Type="Italic">Optimum Experimental Designs</Emphasis>. Oxford, UK: Clarendon Press, 1992.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-642-04898-2_434>10.1007/978-3-642-04898-2_434</a></td><td><b>CrossRef-Meta</b></td>
<td>BookTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Tod M, Padoin C, Louchahi K, Moreau-Tod B, Petitjean O, Perret G. Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1994;22:129&#8211;146.</td><td><a href=http://dx.doi.org/10.1007/BF02353539>10.1007/BF02353539</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibChapter</td><td>Landaw EM. Robust sampling designs for compartmental models under large prior Eigenvalue uncertainties. In: Eisenfeld J, DeLisi C, eds.<Emphasis Type="Italic">Mathematics and Computers in Biomedical Applications</Emphasis>, North-Holland, The Netherlands: Elsevier Science Publishers BV; 1985:181&#8211;187.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Duffull SB, Mentre F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2001;18:83&#8211;89.</td><td><a href=http://dx.doi.org/10.1023/A:1011035028755>10.1023/A:1011035028755</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Mentre F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.<Emphasis Type="Italic">J Pharmacokient Pharmacodyn</Emphasis>. 2001;28:299&#8211;319.</td><td><a href=http://dx.doi.org/10.1023/A:1011583210549>10.1023/A:1011583210549</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Mentre F, Mallet A, Baccar D. Optimal design in random-effects regression models.<Emphasis Type="Italic">Biometrika</Emphasis>. 1997;84:429&#8211;442.</td><td><a href=http://dx.doi.org/10.1093/biomet/84.2.429>10.1093/biomet/84.2.429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Retout S, Duffull S, Mentre F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.<Emphasis Type="Italic">Comput Methods Programs Biomed</Emphasis>. 2001;65:141&#8211;151.</td><td><a href=http://dx.doi.org/10.1016/S0169-2607(00)00117-6>10.1016/S0169-2607(00)00117-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Merle Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:363&#8211;388.</td><td><a href=http://dx.doi.org/10.1023/A:1011534830530>10.1023/A:1011534830530</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2003;30:387&#8211;404.</td><td><a href=http://dx.doi.org/10.1023/B:JOPA.0000012998.04442.1f>10.1023/B:JOPA.0000012998.04442.1f</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibBook</td><td>Danhof M, Karlsson M, Powell RJ, eds. Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling. Part 1 and 2 4th International Symposium on measurement and Kinetics of In Vivo Drug Effects; April 24&#8211;27; Nordwijkerhout, The Netherlands. Leiden, The Netherlands: Leiden University; 2002. 1&#8211;200.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibBook</td><td>Davidian M, Giltiman DM.<Emphasis Type="Italic">Nonlinear Models for Repeated Measurement Data</Emphasis>. New York, NY: Chapman &amp; Hall/CRC; 1995:241.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.2307/1270420>10.2307/1270420</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR22</td><td>BibBook</td><td>Fedorov VV, Hackl P.<Emphasis Type="Italic">Model Oriented Design of Experiments</Emphasis>. New York, NY: Springer-Verlag, 1997.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-4612-0703-0>10.1007/978-1-4612-0703-0</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR23</td><td>BibBook</td><td>Vonesh EF, Chinchilli VM.<Emphasis Type="Italic">Linear and Nonlinear Models for the Analysis of Repeated Measurements</Emphasis>. New York, NY: Marcel Dekker Inc; 1997.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Hooker AC, Foracchia M, Dodds MG, Vicini P. An evaluation of population D-optimal designs via pharmacokinetic simulations.<Emphasis Type="Italic">Ann Biomed Eng</Emphasis>. 2003;31:98&#8211;111.</td><td><a href=http://dx.doi.org/10.1114/1.1533074>10.1114/1.1533074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Foracchia M, Hooker A, Vicini P, Ruggeri A. POPED, a software for optimal experiment design in population kinetics.<Emphasis Type="Italic">Comput Methods Programs Biomed</Emphasis>. 2004;74:29&#8211;46.</td><td><a href=http://dx.doi.org/10.1016/S0169-2607(03)00073-7>10.1016/S0169-2607(03)00073-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibBook</td><td>Larsen RJ, Marx ML.<Emphasis Type="Italic">An Introduction to Mathematical Statistics and Its Applications</Emphasis>. Upper Saddle River, NJ: Prentice-Hall; 1986:248.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.2307/3617085>10.2307/3617085</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Solkner J. Choice of optimality criteria for the design of crossbreeding experiments.<Emphasis Type="Italic">J Anim Sci</Emphasis>. 1993;71:2867&#8211;2873.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Retout S, Mentre F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.<Emphasis Type="Italic">J Biopharm Stat</Emphasis>. 2003;13:209&#8211;227.</td><td><a href=http://dx.doi.org/10.1081/BIP-120019267>10.1081/BIP-120019267</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Sheiner L, Wakefield j. Population modelling in drug development.<Emphasis Type="Italic">Stat Methods Med Res</Emphasis>. 1999;8:183&#8211;193.</td><td><a href=http://dx.doi.org/10.1191/096228099672920676>10.1191/096228099672920676</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1979;25:358&#8211;371.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/cpt1979253358>10.1002/cpt1979253358</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Draper NR, Hunter WG. Design of experiments for parameter estimation in multiresponse situations.<Emphasis Type="Italic">Biometrika</Emphasis>. 1966;53:525&#8211;533.</td><td><a href=http://dx.doi.org/10.2307/2333656>10.2307/2333656</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, ArticleTitle, JournalTitle, FirstPage, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Bennett JE, Wakefield JC. A comparison of a Bayesian population method with two methods as implemented in commercially available software.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1996;24:403&#8211;432.</td><td><a href=http://dx.doi.org/10.1007/BF02353520>10.1007/BF02353520</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1991;19:333&#8211;353.</td><td><a href=http://dx.doi.org/10.1007/BF03036255>10.1007/BF03036255</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1981;9:367&#8211;388.</td><td><a href=http://dx.doi.org/10.1007/BF01059272>10.1007/BF01059272</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1996;60:619&#8211;635.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(96)90210-6>10.1016/S0009-9236(96)90210-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibBook</td><td>Beal S, Sheiner L.<Emphasis Type="Italic">NONMEM User&#8217;s Guide</Emphasis>. San Francisco, CA: University of California; 1992.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1993;25:506&#8211;515.</td><td><a href=http://dx.doi.org/10.2165/00003088-199325060-00008>10.2165/00003088-199325060-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-beta la in humans.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2002;19:1537&#8211;1543.</td><td><a href=http://dx.doi.org/10.1023/A:1020468902694>10.1023/A:1020468902694</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>